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Received 17 March 2010; received in revised form 14 July 2010; accepted 16 July 2010Abstract Human embryonic stem cells (hESCs) offer new avenues for studying human development and disease progression
in addition to their tremendous potential toward development of cell-replacement therapies for various cellular disorders. We
have earlier reported the derivation and characterization of Relicell® hES1, the first fully characterized hESC line generated
from the Indian subcontinent. Recent studies have demonstrated discrete differences among hESC lines, in terms of both their
growth properties and their differentiation propensity. To address some of these issues in the context of hESC research in
India, we have recently generated two new hESC lines: Relicell® hES2 and Relicell®hES3. Both these cell lines were derived
using a combinatorial approach of immunosurgery followed by mechanical surgery for inner cell mass isolation. The cell lines
exhibit the usual hESC characteristics including their ability to differentiate both in vitro and in vivo to yield the three
germinal layers. Whole genome microarray analysis of these cell lines was compared with Relicell®hES1 and it showed that
approximately 9000 genes were expressed by these lines. As expected the expression pattern of these new cell lines bore close
resemblance to that of Relicell®hES1. A majority of the pluripotency genes and the genes known to inhibit various
differentiation pathways were also expressed by these cell lines. We also observed that each of these cell lines expressed a
unique set of genes that are mutually exclusive from each other. These results represent the first detailed characterization of
a set of hESC lines originating from India.
© 2010 Elsevier B.V. All rights reserved.Introduction embryonic germ layers (Reubinoff et al., 2000; Odorico et al.,Human embryonic stem cells (hESCs) are derived from the
inner cell mass (ICM) of preimplantation embryos. The
fundamental characteristics of these cells include pluripo-
tency and the capacity for self-renewal. This confers on hESCs
unlimited replicative ability for extended periods of time
while maintaining an undifferentiated state along with the
capability of differentiating into derivatives of all three⁎ Corresponding authors. Fax: +91 22 67678099.
E-mail addresses: arundhati_mandal@relbio.com (A. Mandal),
asenmajumdar@gmail.com (A.S. Majumdar).
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doi:10.1016/j.scr.2010.07.0012001). Thus, hESCs are considered to be good candidates for
studying various aspects of developmental biology research
as well as a source of cells for tissue regeneration and cell
replacement therapies (Liew et al., 2005).
Derivation and characterization of hESC lines are important
in terms of direct application to human diseases. Since the
establishment of the first hESC lines reported by Thomson and
his group about a decade ago (Thomson et al., 1998), rapid
progress has been made in this research and several studies
(Amit and Itskovitz-Eldor, 2002; Cowan et al., 2004; Park et al.,
2004; Guhr et al., 2006) have described the derivation
and culture of new hESC lines from fresh/frozen morula
(Strelchenko et al., 2004) and/or blastocyst stage embryo.
174 A. Mandal et al.(Mitalipova et al., 2003; Cowan et al., 2004). Despite the use
of different protocols for hESC line derivation and culture
maintenance, by and large all hESC lines express pluripotency-
related genes, e.g., OCT4, NANOG, and SOX2, as well as a
battery of cell surfacemarkers such as SSEA3, SSEA4, TRA-1-60,
TRA-1-81, CD9, and CD90. Characterizations of 57 hESC lines
derived from many different laboratories worldwide by the
International Stem Cell Initiative (ISCI) have demonstrated
remarkable similarities between the lines, although subtle
differences in gene-dependent variations were observed
between these cell lines (Adewumi et al., 2007). Comparative
studies including large-scale gene expression analysis in
multiple hESC lines (Bhattacharya et al., 2004; Richards
et al., 2004) are becoming rather common and also more
advanced. Despite the apparent overall similarity in the
fundamental expression patterns among the hESC lines,
important differences have been noted. The differences
ranging from the growth rates and differentiation patterns,
methylation patterns to karyotypic stability, and changes
associated with long-term propagation in culture of hESC lines
have been frequently reported (Draper et al., 2004; Hoffman
andCarpenter, 2005; Tavakoli et al., 2009). Inaddition, various
hESC lines derived and maintained under identical culture
conditions exhibited significant differences in their ability to
differentiate toward certain lineages as reported in several
cases (Osafune et al., 2008; Mehta et al., in press). These
results seem to indicate that different hESC lines may notTable 1 Establishment of the Relicell®hESC lines




1 D6/3AB Laser Yes
2 D6/3BA Whole Yes
3 D7/3AA Laser Yes
4 D6/4BA Laser Yes
5 D6/4AA Laser Yes
6 D6/3CB Laser No
7 D6/3CB Whole No




10 D6/5BB Nat. Hatching Yes
11 D5/4BB Laser Yes
12 D5/4CB Whole Yes
13 D5/3BB Immunosurgery Yes







17 D6/4CB Whole Yes
18 D6/4CB Nat. Hatching Yes
Abbreviations: P, passage; D, day; NA, not applicable.
aBlastocyst grade was defined according to the criteria presented by G
bMechanical removal of TE from the ICM+TE complex on Day 3/4 waspossess similar differentiation bias in vitro and such differen-
tiation propensity needs to be examined prior to generating
an optimal differentiation protocol for mature cell types
with potential therapeutic applications.
The great majority of well-characterized hESC lines have
been derived from relatively small cross sections of the
human population with limited ethnic diversity. In two recent
independent reports, investigators have determined the
ethnicity of 47 hESC lines using genome-wide single nucleo-
tide polymorphism (SNP) genotyping which reveals that
almost all of these lines were derived from subjects of
European and Middle Eastern origin (Laurent et al., 2010;
Mosher et al., 2010). In light of these findings, it is important
that new hESC lines be derived from populations of diverse
genetic background so that the differential potential, drug
toxicity profiles, and immunological phenotypes (HLA haplo-
type) of these cell lines can be assessed and compared with
the existing hESC lines. In addition, availibility of hESC lines
from embryo donors of diverse origin and ethnic background
may provide a better HLA matching within the population
from which the lines are derived. Although the recent
development of a generation of differentiated cell types
from induced pluripotent stem (iPS) cells may eliminate
the possibility of immune rejection after transplantation
(Takahashi et al., 2007; Maehr et al., 2009), clinical
applicability of such individualized cell therapy remains a













Yes D3 Relicell®hES2 cell line
No D2 P2
No Not done as ICM was
not visible after D2
P0
No D7 P1
No Not done as ICM was
not visible after D2
P0
No Not done as ICM was
not visible after D2
P0
Yes D4 Relicell®hES3 cell line
Yes D4 Contaminated at P1
No D4 P1
No D5 P1
ardner et al. (2000).
done from embryo No. 9 onward.
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we (Mandal et al., 2006) along with other groups (Inamdar
et al., 2009; Kumar et al., 2009) have reported the
generation of hESC lines from the Indian population. In this
current study, we describe the successful derivation of twoFigure 1 (A) Immunostaining profile of Relicell®hESC lines. Undiffe
strongly positive for OCT3/4 (a and g), NANOG (b and h), SSEA-4 (
phosphatase (f and l). Both primary and secondary controls staining o
by flow cytometry shows immunoreactivity (shaded histograms) of th
were directly labeled with phycoerythrin (PE). Isotype-antibody stai
profile of Relicell®hESC lines. Real-time qRT-PCR analysis shows th
NANOG, DPPA5, UTF1, ABCG2, GDF3, and TERT. The expression of ea
gene. Both the cell lines show the presence of these genes with littmore new hESC lines from the Indian population: Relicell®hES2
and Relicell®hES3 from surplus in vitro fertilized (IVF)
embryos. These new cell lines have been simultaneously
maintained in an undifferentiated state in culture for over
1 year. They have been characterized, expanded, frozen, andrentiated cells of each of these cell lines on Day 4 of culture were
c and i), TRA-1-60 (d and j), TRA-1-81 (e and k), and alkaline
ffered negativity. (B) Immunophenotyping of Relicell®hESC lines
ese cells to OCT3/4 (a and b) and SSEA 4 (c and d). The antibodies
ning (green line) shows background fluorescence. (C) Molecular
e expression of the common pluripotent genes OCT3/4, SOX2,
ch gene was normalized to the corresponding levels of 18 s rRNA
le variations in their expression levels.
176 A. Mandal et al.thawed with no loss of pluripotency. Furthermore, we have
compared the characteristics of these hESC lines in terms of
morphology, expression of pluripotency markers, and differ-
entiation capacity both in vitro and in vivo. Microarray analysis
revealed close similarity between our three cell lines,
although each one of these lines expresses a unique set of
genes that may further contribute to our understanding of
human ES cell biology.Results
Derivation and culture of hESC lines
Of the 18 blastocysts, immunosurgery and laser ablation
were performed on 6 samples each, whole embryo manip-
ulation was done on 4, and natural hatching was done for 2
(Table 1). The new hESC lines Relicell®hES2 and Reli-
cell®hES3 were derived with a combinatorial approach of
immunosurgery and mechanical isolation of ICM cells. The
blastocysts (Supplementary Fig. 1, a and d) were initially
exposed to antibody and complement-mediated lysis for
trophectoderm (TE) removal. However, with this exposure
followed by repeated but gentle pipetting of the blastocyst,
the TE cells did not lyse completely and most of these cells
were clumped together with the ICM. Without risking further
damage to the embryos, the mass was plated on a mitotically
inactivated MEF feeder layer. In our earlier experience, we
have often observed that the overgrowth of TE cells
prevented ES cell proliferation. Therefore, in this case, the
TE cells were mechanically separated during the third or
fourth day of culture. This allowed the ICM to proliferate and
subsequently transform into an ES-like colony (Supplemen-
tary Fig. 1, b and e). The initial colony was then mechanically
passaged approximately a week later.
The new hESC lines formed distinct colonies with the
characteristic morphology of human ES cells, such as densely
packed cells with high nuclear to cytoplasmic ratios and having
clearly defined borders (Supplementary Fig. 1, c and f). The
cell lines have been in culture for over 1 year and have been
propagated for more than 80 passages so far.Figure 2 (A) Dendrogram showing hierarchical clustering of total
MEF cells. Clustering was carried out using the cluster analysis packa
was used for the dendrogram formation. The clustering shows close
BG01. * Relicell®hES4 cell line was derived from a PGD analyzed em
will be published elsewhere. (B) Differences in relative express
undifferentiated Relicell®hESC lines. The expression levels of 54 un
expression levels were found comparable in most of them. CD24, DPPA
the cell lines. The high expression of these 54 genes imply that a
consistency of the expression levels of the undifferentiated marker ge
qRT- PCR analysis (Fig. 1B). (C) A heat map representation of all the 7
did not show any detectable probe on the Microarray chip and are th
levels of expression of a single marker gene. Samples 1–3 incl
Relicell®hES3, respectively. High expressions relative to mean are col
significant change in expression levels between mean and sample. (D)
specific cell markers among the three undifferentiated Relicell®hE
lineage-specific markers expressed in all the three Relicell®hESC lines
obtained within the Pb0.01 cutoff range. Only LAMC1 and TUBB show
were found to be weakly expressed. DCN, GSC, LAMB1, MAP2, and TMarker expression in the hESC lines
The undifferentiated state of the hESC lines was confirmed
by evaluating several cell surface markers by immunofluo-
rescence analysis. Colonies of Relicell®hES2 (p10) and
Relicell®hES3 (p11) cell lines uniformly expressed markers
such as OCT-3/4, NANOG, SSEA4, TRA-1-60, and TRA-1-81
(Fig. 1A, a–e and g–k). The cells from each of these cell lines
were highly positive for Oct 3/4 (92%) and SSEA4 (99%) as
quantitated by flow cytometric analysis (Fig. 1B). As
expected the hESC colonies displayed strong alkaline
phosphatase activity (Fig. 1A, f and l).
Real-time RT-PCR was used to quantify the levels of mRNA
expression of 8 selected genes (OCT3/4, SOX2,NANOG,DPPA5,
UTF1, ABCG2, GDF3, and TERT) to determine the undifferen-
tiated ESC state. All the genes were highly expressed in
Relicell®hES2 and Relicell®hES3 cell lines (Fig. 1C).
Microarray analysis of the hESC lines
Gene expression profiles of Relicell®hESC lines
In order to determine the similarities and differences between
the two new Relicell®hESC lines, we performed a whole
genome array analysis using Illumina BeadChip with arrays
containing 24 000 transcripts derived from the Human RefSeq
database which included both full-length and spliced variants.
Gene expression analysis of Relicell®hES1 by microarray has
been reported previously (Pal et al., 2007). The rational for
including Relicell®hES1 in this study was to perform parallel
genome-wide expression analysis of all the three Indian cell
lines that were derived and established in our laboratory.
Although the three Indian hESC lineswere closely related to
each other in comparison to a well-studied line, BG01 (Zeng
et al., 2004; Bhattacharya et al., 2004), gene expression
profiles between Relicell®hES2 and Relicell®hES3 were more
similar to each other than with Relicell®hES1 (Fig. 2A). Our
fourth hESC line, Relicell®hES4 derived from a PGD diagnosed
embryo, was clustered together with Relicell®hES1 as deter-
mined by the Genome Studio cluster package. The complete
characterization and differentiation profiles of Relicell®hES4
will be published elsewhere. The R2 values between eachgenes expressed in all Relicell®hESC lines as well as in BG01 and
ge of Genome Studio software. The Euclidean metric algorithm
association between the four Relicell®hESC lines compared to
bryo. The detailed report on characterization of this cell line
ion levels of undifferentiated cell markers among the three
differentiated marker genes were compared to GAPDH and the
4, and LIN28 were found to be expressed at very high levels in all
ll three Relicell®hESC lines are pluripotent. The data show the
nes (OCT3/4, NANOG, and SOX2) compared with the results of the
9 genes from the list of 85 undifferentiated marker genes (6 genes
erefore excluded from this list). Each row represents the relative
uded three groups of cells, Relicell®hES1, Relicell®hES2, and
ored red. Low expressions are colored green. Black represents no
Differences in relative expression levels of differentiated lineage-
SC lines. Expression levels of 22 representative differentiated
have been shown in comparison to GAPDH. All markers have been
ed some correlation to GAPDH expression whereas other markers
(Brachury) are seen to be differentially expressed.
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Table 2 Differential expression of thirteen undifferentiated markers in Relicell®hESC lines




BMPR1A NM_004329.2 10 Homo sapiens bone morphogenetic protein
receptor, type IA (BMPR1A), mRNA.
aND + +
DPPA5 NM_001025290.1 6 Homo sapiens developmental pluripotency-associated
5 (DPPA5), mRNA.
+ ND ND
DIAPH1 NM_005219.2 5 Homo sapiens diaphanous homolog 1 (Drosophila)
(DIAPH1), mRNA.
+ ND +
FGF13 NM_033642.1 X Homo sapiens fibroblast growth factor 13 (FGF13),
transcript variant 1B, mRNA.
ND + ND
GRB7 NM_005310.2 17 Homo sapiens growth factor receptor-bound
protein 7 (GRB7), transcript variant 1, mRNA.
ND + +
MAP2 NM_002374.3 2 Homo sapiens microtubule-associated protein
2 (MAP2), transcript variant 1, mRNA.
+ + ND
NOG NM_005450.2 17 Homo sapiens noggin (NOG), mRNA. ND + ND
NR5A2 NM_205860.1 1 Homo sapiens nuclear receptor subfamily 5, group A,
member 2 (NR5A2), transcript variant 1, mRNA.
+ ND +
NR6A1 NM_001489.3 9 Homo sapiens nuclear receptor subfamily 6, group A,
member 1 (NR6A1), transcript variant 2, mRNA.
ND + ND
NUMB NM_003744.5 14 Homo sapiens numb homolog (Drosophila) (NUMB),
transcript variant 3, mRNA.
ND + +
TDGF1 NM_003212.1 3 Homo sapiens teratocarcinoma-derived growth
factor 1 (TDGF1), mRNA.
+ ND ND
TERT NM_198253.2 5 Homo sapiens telomerase reverse transcriptase
(TERT), transcript variant 1, mRNA.
+ ND +
UTF1 NM_003577.2 10 Homo sapiens undifferentiated embryonic
cell transcription factor 1 (UTF1), mRNA.
+ ND +
Abbreviation: ND – not detected.
178 A. Mandal et al.duplicate samplewere found tobearound0.99, confirming the
reproducibility of the assay. On filtering the total number of
genes detected by the array (18391 for each cell line) based on
Pb0.01 criteria, we found that the number of genes
significantly expressed in Relicell®hES1, Relicell®hES2, and
Relicell®hES3 were 9245, 9253, and 9276, respectively, out of
which the number of genes common to all three lineswas 7236.
The remaining genes consisting of 2009 for Relicell®hES1, 2017
for Relicell®hES2, and 2040 for Relicell®hES3 were differen-
tially expressed by these cell lines.
As the Relicell®hESCs were cultured over MEF feeders, we
probed the possibility of MEF contamination with the hESC
samples. In a separate set of experiments, we spotted MEF
cRNA along with the hESC samples and found that only 1200
genes were significantly expressed (Pb0.01) (data not
shown) as compared to 9000 plus genes in hESC lines.
However, except for IFITM1, LAMC1, ACTC1, CGB5, and ISL1,
none of the pluripotency-related genes were seen toFigure 3 (A) Venn diagram illustrating the digital gene expression
between the cell lines. All the cell lines were grown under the same
analysis. It shows that around 78% (7236 out of 9308) of the genes are
genes are uniquely expressed by Relicell®hES1, Relicell®hES2, and
commonly expressed among the three lines suggests the presence of a
molecular function of unique signature genes in the Relicell®hESC
function-related genes in all three individual lines. The functional clu
clustering shows the expression of several types of binding genes in th
of these genes have been assigned to more than one molecular funccoexpress in the MEF feeder sample. The coexpression of
the above-noted genes could be due to cross-reacting probes
present in Illumina BeadChip.
Expression of genes known to regulate pluripotency in
Relicell®hESC lines
In recent years, a large dataset on gene expression of
undifferentiated hESCs has been generated using large-scale
experiments such as MPSS, SAGE, and microarray (Richards
et al., 2004; Brandenberger et al., 2004; Liu et al., 2006).
The common goal of all such extensive studies was to come
up with some characteristic markers significant for deter-
mining the pluripotent state of hESCs. In reference to all
these published data on hESCs, we came up with a list of 85
genes which have thus far been reported to be enriched in
hESCs by different investigators worldwide (Abeyta et al.,
2004; Skottman et al., 2005; Liu et al., 2006). This list of 85
genes is the first cumulative list of genes established asprofile of the Relicell®hESC lines and the intersection of genes
culture conditions. Only genes with Pb0.01 were taken for this
common to all the three lines whereas only 0.7, 2.4, and 1.9% of
Relicell®hES3, respectively. The large overlap in genes (7236)
stable core of stemness trancriptome. (B) Pie chart representing
lines. This chart shows the expression of different molecular
stering was done by the DAVID gene ontology tool (GoEASY). The
e three lines identifying their similarity amidst uniqueness. Some
tion.
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180 A. Mandal et al.representative markers of hESC pluripotency. The list also
included the core set of 20 genes established as pluripotency
markers by the ISCI studies on 57 hESC lines (Adewumi et al.,
2007). Fifty-four of these 85 genes were found to be
expressed in all three Relicell®hESC lines (Fig. 2B). Thirteen
genes were found to be variably expressed among the lines
(Table 2) while 12 genes did not show any significant
expression (Supplementary Table 1) in these three lines.
Six genes from this list, namely EBAF, BRIX, XIST, LIN41,
ZNF206, and TDGFB1P, were not detected in the array.
Besides the well-established pluripotency genes such as
OCT3/4, NANOG, SOX2, REX, GDF3, LEFTB, LIN28, and
DNMT3B, many other genes such as CD24, DPPA4, NODAL,
and FOXD3 are believed to be important in maintaining the
undifferentiated state. Most of these markers were enriched
in all three Relicell®hESC lines. Twelve of the 20 ISCI study
genes were present in these three lines (Supplementary
Figs. 2A and C) whereas 4 genes, TERT, UTF1, GRB7, and
TDGF1, were variably expressed. We could not detect the
expression of the remaining 4 genes (FGF4, BRIX, XIST, and
EBAF) reported in the ISCI study in any of our cell lines. These
data taken together suggest that all three Relicell®hESC lines
show similar, but not identical, patterns of gene expression
with respect to the markers that are indicative of pluripo-
tency. The expression levels of the pluripotency markers
clearly indicate the self-renewal state of our hESC lines. A
complete analysis of all the 79 pluripotency markers has
been depicted in the form of a heat map (Fig. 2C).
Next, we determined the expression pattern of few
differentiated cell markers that were shown to be present
in other well-characterized hESC lines at the undifferentiat-
ed stage. Of the 13 genes that were examined in the ISCI
report (Adewumi et al., 2007) ACTC1, AFP, COL1A1, COL1A2,
EOMES, LAMA1, and Sox17 were found to be expressed by all
three Relicell®hESC lines (Supplementary Figs. 2B and 2C).
Interestingly, GATA4 was detected only in Relicell®hES2 and
Relicell®hES3 cell lines but not in Relicell®hES1. In contrast,
GATA6 was expressed only by Relicell®hES2. The remaining 4
genes were not expressed by any of our lines. We alsoTable 3 List of unique genes with no known function
Cell line Gene symbol Illumina search key Chromosome
Relicell®hES1 LOC255374 ILMN_5827 7
Relicell®hES2 FLJ10324 ILMN_3564 7
FLJ13236 ILMN_28329 12
LOC51057 ILMN_30040 2
Relicell®hES3 FLJ22374 ILMN_22269 7
LOC222967 ILMN_175454 7
LOC51149 ILMN_15092 5
LOC606495 ILMN_4186 1measured the expression of 48 genes that has been shown to
be associated with the three germ layers and observed that
17 of these genes are expressed by all three lines and 5 genes
(DCN, GSC, LAMB1, MAP2, and T) show a variable expression
among the lines (Fig. 2D). It is not clear whether these
differentiated cell-associated genes are expressed by the
undifferentiated hESCs or in a population of cells that have
spontaneously differentiated in our culture. However, none
of the differentiated markers such as ALB, NEUROD1, INS,
MHC, OLIG2, and CYP3A4 known to be expressed in mature
cells were present in these cell lines, indicating their
undifferentiated state.
Presence of unique signature genes in Relicell®hESC lines
A Venn diagram depiction of the unique and common genes is
shown in Fig. 3A. While 68 unique genes were found in
Relicell®hES1, the number went up to 228 in Relicell®hES2
and 176 in Relicell®hES3. Further elucidation of the nature of
the unique signature genes classified them into three
ontology domains that included biological processes, cellular
components, and molecular function. It was observed that a
high percentage of the preferred ontology groups included
protein binding genes (PRKCZ, ILK, GABBR1, DCN, etc. in
Relicell®hES1, Fig. 3B, a), calcium ion binding genes (STAT4,
MYL4, MIER3, MAN1A2, etc. in Relicell®hES2, Fig. 3B, b), lipid
binding genes (ULBP1, DGKA, APOA4, SNAP91, etc. in
Relicell®hES3, Fig. 3B, c). Other closely related ontology
types such as ATP binding, transcription factors, transcrip-
tion regulation, voltage gated ion channel activity, and zinc
ion binding were also found to functionally designate the
unique genes. The significance of these markers in the
context of pluripotency or differentiation ability of these
hESC lines is difficult to ascertain at this time.
The list of unique genes also included genes with no
known functions (Table 3). The number of unique genes with
no known function was found to be 1 for Relicell®hES1, 3 for
Relicell®hES2, and 4 for Relicell®hES3. Four of these 8 genes
present in Relicell®hES1, Relicell®hES2, and Relicell®hES3
with unknown function were mapped in chromosome 7. Thelocation Definition
Homo sapiens similar to hypothetical protein
MGC49416 (LOC255374), mRNA.
Homo sapiens hypothetical protein FLJ10324
(FLJ10324), mRNA.
Homo sapiens hypothetical protein FLJ13236
(FLJ13236), mRNA.
Homo sapiens hypothetical protein LOC51057
(LOC51057), transcript variant 1, mRNA.
Homo sapiens hypothetical protein FLJ22374
(FLJ22374), mRNA.
Homo sapiens hypothetical protein LOC222967
(LOC222967), mRNA.
Homo sapiens hypothetical LOC51149 (LOC51149),
transcript variant 2, mRNA.
Homo sapiens hypothetical protein LOC606495
(LOC606495), mRNA.
181Derivation, characterization, and gene expression profile of two new human ES cell lines from Indiafunctional determination of these unknown genes may reveal
important clues to the signature identities of the three
Relicell®hESC lines.
Signaling pathway analysis
Several different signaling pathways have been reported to
be involved in maintaining hESC pluripotency. Here we have
looked into the expression patterns of the participating
components (www.genome.jp/kegg/pathway.html) of WNT,
TGFβ, and Nodal/Activin pathways in all the Relicell®hESC
lines. TheWNT target genes c-MYC, JUN, FOS, and CycD were
found to be present in all the three cell lines. Though there is
a variable expression of FRZ receptors and β-catenin is not
detected in any of the lines, nevertheless a β-catenin-like
protein CTNNBL1 is found to be considerably enriched in all
the cell lines. The TGF-β pathway genes such as TGFBR2,
TGFBR3, SMAD3, and SMAD4 are present in all the lines. The
inhibitors such as THBS, CUL1, and RBX were found to be
enriched in all the lines. The TGF-β target genes EP300, SP1,
and E2F4/E2F5 are also present in these lines. We also
observed very high expression of LEFTY and FST in the hESC
lines, indicating possible inhibition of the Nodal/Activin
pathway, though Nodal is found to be expressed in all our
lines. A tabular depiction of the genes from different
pathways and their presence in the three hESC lines is
shown in Supplementary Table 2.
Genetic stability and identity of the hESC lines
Karyotype analysis showed that the two new hESC lines main-
tained a stable diploid normal karyotype. Both Relicell®hES2
and Relicell®hES3 showed normal 46XX distribution (Supple-
mentary Fig. 3). Frozen–thawed samples of these cell lines
showed normal karyotype as well.
We have developed a comprehensive database of DNA
profiles for each of our cell line based on HLA typing and STR
loci distribution. Our results from the two new hESC lines
revealed that these cells are of heterozygous HLA genotype
except for homozygous DQB locus in Relicell®hES3 cell line
(Supplementary Table 3). The data also showed that
Relicell®hES2 and Relicell®hES3 cell lines have different
HLA genotypes which may be useful for identification.
Sixteen STR loci were analyzed for the hESC lines and each
cell line showed distinct sets of STR loci, indicating that they
were derived from genetically different embryos (Supple-
mentary Table 4).
In vitro and In vivo differentiation potential
Spontaneous differentiation of hESCs into various lineages
via embryoid body (EB) formation was determined by marker
expression at the molecular level. qRT-PCR results show that
both hESC lines expressed genes of ectoderm (Nestin, Beta-
tubulin, and NFH; Fig. 4A, panel a), mesoderm (HAND1, T,
and GATA4; Fig. 4A, panel b), and endoderm (AFP, Sox17,
and HNF4a; Fig. 4A, panel c) lineages. The level of expression
of a particular gene was found to vary at different stages of
differentiation for each cell line, indicating differential up or
down regulation during the differentiation period. Since the
Relicell®hES2 cell line had not generated teratoma in SCID
mice so far (see below), these cells were allowed tospontaneously differentiate into EBs to determine the
presence of cellular markers belonging to the three germinal
lineages. Immunostaining of EBs showed that the differen-
tiated cells of Relicell®hES2 expressed ectodermal marker,
Nestin (Fig. 4B, panel a), mesodermal marker, GATA4
(Fig. 4B, panel b), and endodermal marker, HNF4a (Fig. 4B,
panel c).
The in vivo differentiation potential of the two lines was
further evaluated by observing teratoma formation in SCID
mice. The developing or fully developed tumors were
dissected between 8 and 12 weeks after the injection of
hESCs from the Relicell®hES3 line. The resulting teratomas
contained derivatives of all the three germ layers: ectoderm
(neurons, keratin, and hair follicles), mesoderm (bone,
cartilage, artery, and adipocytes), and endoderm (respira-
tory track epithelium, intestinal epithelium, and renal
development) (Fig. 4C). This demonstrates that this hESC
line is pluripotent and capable of differentiating into all
three germ layers in vivo. No teratoma formation has yet
been observed with the Relicell®hES2 cell line in immuno-
compromised mice.Discussion
Human embryonic stem cells are commonly isolated from the
ICM of the expanded blastocyst or compacted morula,
obtained from spare donated embryos after IVF treatment.
In this study, two new hESC lines were derived from a similar
source of embryos obtained from the Indian population. The
method used for derivation was chosen keeping in view the
embryo quality and specifically the size of the ICM. For good
quality blastocysts, immunosurgery or laser ablation was
used whereas for average and poor quality as well as for
hatching blastocyst, a whole embryo plating method was
performed (Kim et al., 2005). We observed that the
mechanical separation of the ICM from the TE cells during
the first few days of the culture was useful in terms of ICM
outgrowth and establishment of ES cell colony. This is
applicable both for whole embryo culture and cases where
TE cells remain attached to ICM post immunosurgery.
Although other studies (Heins et al., 2004; Ellerstrom
et al., 2006) have used similar techniques to isolate the
ICM for derivation of hESC lines, none of them suggested
such early separation of TE cells followed by fresh plating
of ICM. Thus it appears from our data that mechanical
teasing of hyperproliferative TE cells is a better method
for increasing the chances of ICM survival and ES cell line
derivation.
In accordance with previously reported studies, we have
observed the usual characteristics of hESCs in these newly
established lines in terms of cell marker expression pattern,
stability, identity, and ability to differentiate both in vitro
and in vivo. All these cell lines expressed the stem cell-
specific surface markers such as SSEA4, TRA-1-60, TRA-1-81,
and transcription factors OCT3/4, NANOG, and SOX2, and
maintained their genomic stability and pluripotency for more
than 80 passages, as demonstrated by karyotyping and the
ability to spontaneously differentiate under in vitro and in
vivo conditions. HLA profile and STR genotyping status have
established the unique identity for each of these hESC lines.
Relicell®hES2 and Relicell®hES3 cells readily form EBs which
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some differences in the expression of lineage-specific genes.
Representation of the three germ layers was observed in the
Relicell®hES3 cell line in teratoma which further elucidated
its pluripotent nature.
To our knowledge, this is the first comprehensive study of
genome-wide microarray analysis of three hESC lines of
Indian origin. Of the approximate 9000 genes expressed by
the Relicell®hESC lines, 7236 transcripts are common to all
three cell lines including the conventional pluripotency
markers such as OCT3/4, NANOG, SOX2, DNMT3B, LIN28,
and LEFTY 1/2. The presence of OCT3/4, SOX2, and NANOG
was further confirmed by qRT-PCR as well as by immunos-
taining. When we compared our data with those of the ISCI
report, we found that all but 4 genes are present in our lines.
Though TERT, UTF, and TDGF were not detected universally
in our lines by Illumina Bead array, their expression was
confirmed by RT/qRT-PCR, indicating one of the potential
shortcomings of microarray analysis. Our analysis of 85
pluripotency-related genes revealed that 54 of these genes
were common among all the three lines while 13 genes were
differentially expressed. The variable expression of DPPA5,
TERT, TDGF1, and UTF1 among various Relicell®hESC lines
shows an underlying difference between the three charac-
teristically similar lines. Eighteen of the 85 genes absent in
our three lines included 6 genes that had no detectable
probes in the chip. This group of genes includes LIN41, EBAF,
XIST, ZNF206, TDGFB1P, and BRIX. Similar cases of unde-
tectable probes for markers have been reported previously
(Liu et al., 2006).
In addition to the commonly expressed and unique
signature genes, all three Relicell®hESC lines expressed
certain differentiation-associated markers such as SOX17,
GSC, DCN, GATA4, and GATA6. Brachury (T) expression was
detected in undifferentiated Relicell®hES1 and Relicell®hES2
cells, but not in Relicell®hES3. Similarly, GSC expression was
observed in Relicell®hES2 only and DCN gene in the
Relicell®hES1 cell line. Expression of differentiated cell-
specific markers by undifferentiated hESCs has been
reported earlier (Adewumi et al., 2007; Zeng et al., 2004).
Considering the fact that hyperproliferative hESCs are in a
dynamic state, spontaneous differentiation toward trophec-
toderm and other extraembryonic lineage of cells may
account for the differentiated cell marker expression. In
addition, the expression of these genes may be indicative ofFigure 4 (A) In vitro differentiation potential of Relicell®hESC line
ectoderm-, mesoderm-, and endoderm-specific genes between the
compared to its own undifferentiated cells. Panel (a) shows a compar
5, 10, 15, and 20 of differentiation. Relicell®hES2 exhibited a high
Relicell®hES3. Panel (b) shows a comparison of expression levels
differentiation. Relicell®hES2 and Relicell®hES3 showed high exp
expression of GATA4 and T till Day 20. Panel (c) shows a comparison
10, 15, and 20 of differentiation. Relicell®hES2 and Relicell®hES3 exh
showed expression levels of SOX17 and HNF4a till Day 20 of diffe
differentiated Day 30 embryoid body sections of the Relicell®hES2
nestin (a), mesodermal marker, GATA4 (b), and endodermal lineage
DAPI. Scale bar=200 μm (a and b) and 100 μm (c). (C) In vivo differe
developed by Relicell®hES3 cells in SCID female mice. Sections wer
Teratomas contained multidifferentiated tissues. Shown here are
sebaceous gland and hair follicles (a); mesoderm, artery (b); and endifferentiation bias of these cell lines toward a specific
lineage. This remains a hypothesis that needs to be
experimentally authenticated.
Signaling pathway analysis also revealed important clues
to the molecular state of the hESCs. Components of crucial
pathways reported to be involved in maintaining pluripo-
tency such as WNT and TGFβ were found to be commonly
present in all three lines. WNT signaling has been implicated
in the self-renewal of hESCs (Sato et al., 2004). Several WNT
signaling genes such as WNT3, CTNNBLP1, LEF, TCF3, and
CycD are commonly present in all three Relicell®hESC lines.
Expression of TCF3 has been reported to be involved in
maintenance of pluripotency in mESCs (Tam et al., 2008).
WNT3a is variably present between these lines. Though
down regulation of GSK3β is involved in β-catenin stabili-
zation, low levels of the inhibitor were found to be present
in all the lines. Microarray data presented here show that
many of the TGFβ signaling components are present in all
three lines. TGFβ pathways are likely to be critical for the
maintenance of the undifferentiated state of hESCs (Sato et
al., 2003; Brandenberger et al., 2004). The Activin/Nodal
pathway genes such as ACVR1 and SMAD2/4 are present in all
these lines. Potent inhibitors of the activin/nodal pathway
such as LEFTY2 and FST are found to be considerably
enriched, indicating a tight regulation of the pathways in our
cell lines. Similarly, for the BMP pathway the product ID1 is
enriched in all the three Relicell®hESC lines (data not
shown), suggesting that BMP signaling is blocked in these cell
to prevent differentiation or to maintain the undifferenti-
ated state. ERK (MAPK1) which is an inhibitor of this pathway
was also found to be present in all the three lines. An overall
analysis of the signaling pathways indicates an intriguing
molecular environment within the hESC lines wherein both
antagonists and agonists of the participating pathways are
present. The coordinated expression of all these molecules
indicates that these signaling pathways are important and
are tightly controlled for proper growth and differentiation
of hESCs and in maintaining the undifferentiated state of
these cells.
In addition to the hESC lines reported here, other groups
have recently reported derivation of new hESC lines from the
Indian population (Inamdar et al., 2009; Kumar et al., 2009).
In light of the enormous genetic diversity that exists within
the Indian population, comparative data on genetic and
ethnic background of these hESC lines may provide importants. qRT-PCR analysis shows differences in the expression levels of
two Relicell®hESC lines. The Y-axis plots the fold expression
ison of expression levels of the ectodermal-specific genes at Days
er expression level of Nestin, NFH, and Tubulin as compared to
of the mesoderm-specific genes at Days 5, 10, 15, and 20 of
ression levels of HAND1 whereas only Relicell®hES2 showed
of expression levels of the endodermal-specific genes at Days 5,
ibited a higher expression level of AFP while Relicell®hES2 alone
rentiation. (B) Immunofluorescence staining of spontaneously
cell line shows high expression for ectodermal lineage marker,
marker, HNF4a (c), along with respective nuclear staining with
ntiation potential as shown by histological analysis of teratomas
e examined histologically after Hemotoxylin and Eosin staining.
the derivatives of ectoderm, surface epithelium along with
doderm, renal development (c). Scale bar=100 μm.
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screening and regenerative medicine applications.Conclusion
We have established two new hESC lines and characterized
them extensively. At present, our lab has developed the
largest number of characterized hESC lines in India.
Determination of the differentiation propensity of these
cell lines will help us to understand the finer differences
among these lines in future experiments. These studies are
currently under investigation.Materials and methods
Derivation of human ES cell lines
For derivation of hESC lines, spare embryos generated at our
IVF center were used. These were donated by the patients
after their informed consent and Institutional Committee for
Stem Cell Research and Therapy (IC-SCRT) approval was
obtained for this research. Eighteen such embryos were
cultured to the blastocyst stage as described previously
(Mandal et al., 2006). The blastocysts were graded according
to the Gardner et al. method (2000). To isolate ES cells,
mainly four techniques were applied. (1) Immunosurgery was
done as follows; the zona pellucida (ZP) of the blastocysts
was removed by Pronase (Sigma, 0.5%, 90 s) digestion. The
zona-free blastocysts were incubated with anti-human whole
serum antibody (Sigma, 1:10, 30 min.) and then exposed to
guinea pig complement (Sigma, 1:4, 15 min.). The embryo
mass was then plated on an in-house-derived mouse
embryonic fibroblast (MEF) feeder layer which was mitoti-
cally inactivated using mitomycin C (Sigma, 10 μg/ml). The
media were partially exchanged 2 days later. On the third
day of primary plating, the ICM clump was removed
mechanically from the rest of the trophectoderm monolayer
with a finely pulled Pasteur pipette and replated on a fresh
feeder layer. (2) Laser ablation was achieved using a
continuous 1.48.mu.m noncontact diode laser (Saturn Laser
System, Research Instruments Limited, UK) for thermal
dissolution of the ZP. This was followed by TE cell ablation,
by giving 3–4 pulses to cause photolysis. The resulting
embryo mass was then washed several times in ES medium
and placed on a feeder layer. (3) For poor or average quality
blastocysts, the blastocysts were treated with Pronase
(Sigma 0.5%, 90 s) followed by direct plating on a feeder
layer dish. (4) For deriving hESC lines from Day 6 spontane-
ously hatching blastocysts, the blastocysts were directly
plated on the feeder layer to allow natural hatching to take
place. After the embryo was observed to have attached on
the feeder plate, mechanical removal of ICM was performed
3 days later to derive the ES cells as described above.
Every 5 days, colonies were subcultured by mechanical
dissociation as described earlier (Mandal et al., 2006).
Culture media were changed every day. The hESCs were
propagated in medium containing 79% DMEM/F12 (Invitro-
gen), 20% ES tested FBS (Hyclone, USA), 1% nonessential
amino acid solution (Invitrogen), 1 mM glutamine (Invitro-
gen), 0.1% β-mercaptoethanol (Sigma), 15 ng/ml basicfibroblast growth factor (bFGF; R&D Systems), and 10 ng/
ml human leukemia inhibitory factor (hLIF, Sigma). FBS was
replaced with 20% of serum replacement (Invitrogen) after
the first 15 passages. Also hLIF was withdrawn from the
media during this time.
Immunofluorescence, alkaline phosphatase staining,
and flow cytometry
Undifferentiated hESC colonies were grown in 2-well
chamber slides, fixed in freshly prepared 4% paraformalde-
hyde, and permeabilized with 0.2% Triton X-100 (Sigma) in
PBS. The nonspecific binding sites were blocked with 1% BSA
in PBS. The cells were then incubated overnight at 4 °C with
primary antibodies (OCT3/4; Santa Cruz Biotechnology
1:100, NANOG; 1:100, SSEA4; 1:40, TRA-1-60; 1:40, TRA-1-
81; 1:40, Chemicon). After three washings with PBS, cells
were incubated with appropriate FITC-conjugated secondary
antibody for 1 h. For staining serial sections of embryoid
bodies, the slides were dewaxed and permeabilized with
Triton X-100. The preparations were blocked with 10% goat
serum for 1 h followed by incubation with the primary
antibody in a humidified chamber for 2 h. The following
antibodies were analyzed: Nestin (Chemicon, 1:50), GATA4
(Chemicon, 1:50), and HNF4a (Chemicon, 1:50). Cells were
washed with PBS containing 0.05% Tween 20 and incubated
for 30 min at 37 °C with the secondary antibody, anti-mouse
Alexa 568 or anti-rabbit Alexa 488 (Invitrogen, CA, USA,
1:500). Nuclei were counterstained with DAPI. The cells were
observed under a fluorescence microscope (Nikon Eclipse
E600, Kanagawa, Japan) to evaluate the stained areas.
Histological staining for alkaline phosphatase was carried
out using a commercially available kit (Chemicon) following
the manufacture's instructions.
For flow cytometric analysis, hESCs were first mechani-
cally separated from the feeder layer followed by single cell
dissociation using TrypLE Select (Invitrogen) enzyme. The
cells were then stained with phycoerythrin (PE)-labeled
OCT3/4 and SSEA-4 (BD Pharmingen) along with the
respective isotype control. For staining with OCT3/4, the
cells were first fixed and permeabilized in Cytofix/Cytoperm
Fixation/Permeabilization Solution (BD). Cells were ana-
lyzed by a FACScaliber Flow Cytometer (BD Biosciences, San
Jose, CA). Ten thousand events were acquired and analyzed
by CellQuest software.
Real-time PCR
Total RNA was isolated using the RNeasy mini kit (Qiagen,
Inc., Valencia, CA) according to the manufacturer's recom-
mendations followed by cDNA synthesis using superscript
reverse transcriptase (Invitrogen). For real-time PCR, ap-
proximately 50 ng of cDNA template was mixed with 2X PCR
mix (Applied Biosystems, Foster City, CA) and diluted to 1X
with 100 nM primers and water. Predesigned Assay on
Demand TaqMan probes and primers were obtained from
Applied Biosystems (ABI). Quantitative RT-PCR was per-
formed on an ABI iCycler. PCR analyses were conducted in
triplicates for each sample and the results were analyzed
using qbase software (Sequence Detection Software Ver
1.2.2, 7500 Systems, ABI). Relative quantitation of gene
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normalization against endogenous 18 S ribosomal RNA (ABI)
by using the ΔCt method of quantitation. Fold changes were
calculated as 2- ΔΔCt.Microarray analysis
The cells were collected at a low passage for the
Relicell®hESC lines (Relicell®hES2, p24, and Relicell®hES3,
p29) as well as from the previously characterized hESC
lines, Relicell®hES1 (p30) and BG01 (p29). The hESC
colonies with typical undifferentiated morphology were
selected carefully and manually separated and collected
so as to avoid any MEF contamination. Total RNA from
each sample was isolated using the RNeasy mini kit
(Qiagen, USA). The RNA samples were first qualified for
microarray studies using a bioanalyzer (2100 Bioanalyzer,
Agilent Technologies, CA, USA). Five hundred (500) ng of
total RNA was used as a starting material for the
microarray sample preparation. The sample preparation
was carried out according to Illumina guidelines using an
Ambion kit (Ambion Inc., TX, USA). A total of 750 ng
purified cRNA labeled with UTP-biotin was used for
hybridization and stained with Cy3. Samples were added
in duplicates and processed using Illumina Genome Studio
software. Data analysis was carried out using the gene
expression analysis approach. The data were analyzed for
functional clustering using an online software tool DAVID
(http://david.abcc.ncifcrf.gov/home.jsp).Karyotyping
Karyotype analysis was performed using standard methods
of colcemid arrest and G-banding techniques. The hESCs
were treated with colcemid (2 μg/ml) for 4 h followed by
dissociation with prewarmed TrypLE Select. After neu-
tralization with ES medium, the cells were resuspended in
hypotonic KCl solution (0.0375 M) for 25 min. The cells
were then fixed with Carnoy's fixative (glacial acetic
acid:methanol; 3:1) and dropped onto wet precleaned
slides. Chromosome spreads were Giemsa-banded and
photographed using an Olympus BX40 microscope, and
images were captured using a cyto vision digital imaging
system.HLA typing and STR genotyping
HLA profiling and STR genotyping were performed at
GlobalStem Inc. (Rockville, MD, USA). HLA typing was done
to determine the alleles present in each HLA locus on
chromosome 6 using sequence-specific primers. The HLA –A,
B, C, DR, and DQ alleles were analyzed.
STR profiling was done by multiplex PCR to simultaneously
amplify the amelogenin gene and 15 highly polymorphic
markers in the human genome. Loci analyzed included
D8S1179, D21S11, D7S820, CSF1P0, D3S1358, TH01,
D13S317, D16S539, D2S1338, D19S433, vWA, TPOX, D18S51,
D5S818, and FGA.In vitro differentiation potential
To assess the in vitro differentiation potential, hESC colonies
from confluent cultures were manually cut into clumps of
approximately 100–150 cells. These clumps were then
cultured in low attachment bacteriological dishes (Nunc) to
induce embryoid body formation. EB culture media were
composed of 79% DMEM/F12 (Invitrogen), 20% SR (Invitro-
gen), 1% nonessential amino acid solution (Invitrogen), 1 mM
glutamine (Invitrogen), and 0.1% β-mercaptoethanol
(Sigma). Samples were collected at different time points: –
initiation of EB formation (undifferentiated hESC; Day 0) and
EB cultures on Days 5, 10, 15, and 20 and RNA was extracted
from these samples for each time point. The expression
profiles of the various lineage markers were determined in
these samples by qRT-PCR for both hESC lines.
Expression of the lineage markers at the cellular level was
determined in EBs by culturing them in suspension for 30 days
followed by immunostaining of the serial sections with
antibodies specific for ectoderm (Nestin), mesoderm (GATA4),
and endoderm (HNF4a). The details are provided above.
In vivo differentiation potential
Similar to our earlier reported Relicell®hES1 (Pal et al.,
2007); Relicell®hES2 and Relicell®hES3 were assessed for
pluripotency in vivo by teratoma formation in SCID mice.
Approximately, 7×106 undifferentiated cells were injected
intramuscularly as clumps into four SCID mice (C.B-17) for
each cell line. The mice which developed teratoma were
sacrificed after 8–12 weeks and tumors were excised and
fixed in 4% paraformaldehyde (Sigma) and H and E staining
was performed for histological analysis.
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selected from the ISCI report in Relicell®hESC lines.
Supplementary Fig. 2B. Status of differentiated markers
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